Fluor Corporation (NYSE:FLR) said yesterday that it landed a contract to build Novo Nordisk‘s (NYSE:NVO) $2 billion diabetes active pharmaceutical ingredient manufacturing facility in Clayton, North Carolina. Since Denmark-based Novo Nordisk announced plans for the facility in August 2015, Fluor has been providing basic design services for the project.

The manufacturing facility will measure 830,000 square feet and provide approximately 700 new jobs when it is complete. At peak construction, the project will bring on board almost 2,500 craft employees and subcontractors. Irving, Texas-based Fluor said it anticipates that construction for the project will finish in mid-2019.

“Fluor is honored to have the opportunity to assist Novo Nordisk in building this world-class facility in North Carolina to provide modern treatments to diabetes patients,” Fluor’s president of life sciences & advanced manufacturing business Juan Hernández said in prepared remarks. “This project is the single largest life sciences facility investment in North Carolina’s history, which fits well with Fluor’s legacy of building numerous significant life sciences and manufacturing projects in the southeast United States.”

“Novo Nordisk selected Fluor for this critical project, the largest in our history, based on their strong safety culture, technical competence in the life sciences industry and ability to deliver the full scope of work,” Nordisk’s senior VP Morten Nielsen added. “We look forward to continued strong cooperation for the success of this project.”